Supriya Lifescience Successfully Completes USFDA Inspection with 'Voluntary Action Indicated' Status
Supriya Lifescience Limited recently underwent an inspection by the United States Food and Drug Administration (USFDA) at its manufacturing facility in Maharashtra, India. The inspection took place at the facility located in Lote, Parshuram Industrial Area, and spanned from February 2, 2026, to February 6, 2026.The USFDA inspection concluded with the issuance of a Form 483, which contained one minor observation. Supriya Lifescience Limited confirmed that the company adequately addressed this observation. Following this action, the company received the Establishment Inspection Report (EIR) indicating 'Voluntary Action Indicated' (VAI), signaling a successful completion of the inspection process.
The company affirmed its continuing dedication to maintaining full compliance with current Good Manufacturing Practice (cGMP) requirements across all its manufacturing facilities.
SUPRIYA Stock Price Movement
Shares of Supriya Lifescience Limited are rallying to ₹644.7 as of 11:49 AM, gaining 3.86% in live trading. The stock is experiencing high investor interest, trading on a volume of 124,795 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.